Questionnaire survey of angiogenesis inhibitor-related oral complications based on a nation-wide study in Japan.

Published on Jan 1, 2021in Journal of Dental Sciences1.034
· DOI :10.1016/J.JDS.2020.01.004
Shin-ichi Yamada18
Estimated H-index: 18
(Shinshu University),
Hiroshi Kurita37
Estimated H-index: 37
(Shinshu University)
+ 6 AuthorsYutaka Imai1
Estimated H-index: 1
(Dokkyo Medical University)
Abstract Background/purpose The prevalence of oral adverse events and dental treatments related complications during the molecular targeted drugs therapy remains unclear. The purpose of this study was to investigate the contents of dental treatment-related complications in Japanese patients during molecular targeted therapy. Materials and methods The nation-wide survey of dental treatment related complications was performed by the Japanese Society of Dentistry for Medically Compromised Patient as retrospective cohort study. Results Among 212 dentists, 87.3% recognized the possibility of dental treatments related complications in patients with angiogenesis inhibitors. The oral adverse events including dental treatment-related complications associated with angiogenesis inhibitors were 79 cases. In patients with angiogenesis inhibitors, 73.4% of patients were administrated with bevacizumab. The average administration period of angiogenesis inhibitors was 14.0 ± 10.0 months. As the dental treatment related complications, delayed wound healing was most commonly seen in 45 patients (57.0%), followed by osteonecrosis of the jaw in 25 (31.6%). The triggered factor of complications was tooth extraction in 51 cases (96.2%). Conclusion The extraction of the tooth with pre-existing inflammation may be suggested as one of risk factors for angiogenesis inhibitor-related dental treatment complications.
#1Raquel D’Aquino Garcia Caminha (USP: University of São Paulo)H-Index: 3
#2Gabriela Moura Chicrala (USP: University of São Paulo)H-Index: 1
Last. Paulo Sérgio da Silva Santos (USP: University of São Paulo)H-Index: 20
view all 4 authors...
RESUMO Tracar o perfil dos pacientes que desenvolveram osteonecrose dos maxilares associada a agentes antiangiogenicos e identificar os tratamentos realizados atualmente no manejo odontologico. Foi realizada busca nas bases de dados PubMed®/Medline® e Scopus por meio dos descritores “osteonecrosis AND antiangiogenic therapy”, sendo utilizados os criterios de inclusao: artigos publicados em ingles, relato de caso, disponiveis on-line e por periodo ilimitado. Apos analise dos 209 artigos encontrad...
1 CitationsSource
#1Takumi Hasegawa (Kobe University)H-Index: 18
#2Saki Hayashida (Nagasaki University)H-Index: 10
Last. Takahide Komori (Kobe University)H-Index: 11
view all 20 authors...
Summary Root amputation, immunosuppressive therapy, mandibular tooth extraction, pre-existing inflammation, and longer duration of treatment with bone-modifying agents were significantly associated with an increased risk of medication-related osteonecrosis of the jaw. Hopeless teeth should be extracted without drug holiday before the development of inflammation in cancer patients receiving high-dose bone-modifying agents.
19 CitationsSource
#1Emmanuelle VigariosH-Index: 10
#2Joel B. Epstein (Cedars-Sinai Medical Center)H-Index: 90
Last. Vincent SibaudH-Index: 20
view all 3 authors...
Development of biological targeted therapies and immune checkpoint inhibitors has redefined the treatment for many cancers; however, the increasing use of new protocols has led to physicians observing a new spectrum of toxicities. To date, oral adverse events induced by these new anticancer therapies have been mainly reported using nonspecific terminology (“stomatitis,” “mucosal inflammation,” “mucositis”) and remain poorly characterized, with the exception of mammalian target of rapamycin (mTOR...
62 CitationsSource
#1Kiyohiko Hatake (JFCR: Japanese Foundation for Cancer Research)H-Index: 38
#2Toshihiko DoiH-Index: 61
Last. Kuniaki Shirao (Oita University)H-Index: 4
view all 6 authors...
Background: Bevacizumab (Avastin ® ) was approved in Japan in April 2007 for patients with advanced or metastatic colorectal cancer. To address the limited clinical experience in Japanese patients, a post-approval surveillance study was undertaken in bevacizumab-treated patients in Japan. Methods: Bevacizumab (5 or 10 mg/kg every 2 weeks) was administered with chemotherapy; patients were observed for 26 weeks from initiation of treatment. The primary objective was to investigate the incidence of...
12 CitationsSource
#1Kaoru AkiyamaH-Index: 1
#2Masahiro SaitoH-Index: 1
Last. Hitoshi KawamataH-Index: 22
view all 6 authors...
1 CitationsSource
#1Roberto Marino (UNITO: University of Turin)H-Index: 7
#2Fabio Orlandi (UNITO: University of Turin)H-Index: 36
Last. Monica Pentenero (UNITO: University of Turin)H-Index: 24
view all 5 authors...
: Since the discovery of bisphosphonate-related osteonecrosis of the jaw, there has been increasing evidence in recent years of osteonecrosis induced by drugs other than bisphosphonates, mainly agents with antiangiogenic and antiosteoclastic activity. Mandibular osteonecrosis was observed in a 51-year-old female with medullary thyroid cancer receiving cabozantinib, a new tyrosine kinase inhibitor having antiangiogenic activity. The bone necrosis appeared after a dental extraction. The clinical, ...
36 CitationsSource
#1Salvatore L. Ruggiero (SBU: Stony Brook University)H-Index: 25
#2Thomas B. Dodson (UW: University of Washington)H-Index: 59
Last. Felice O'Ryan (Kaiser Permanente Oakland Medical Center)H-Index: 18
view all 7 authors...
Strategies for management of patients with, or at risk for, medication-related osteonecrosis of the jaw (MRONJ) were set forth in the American Association of Oral and Maxillofacial Surgeons (AAOMS) position papers in 2007 and 2009. The position papers were developed by a special committee appointed by the board and composed of clinicians with extensive experience in caring for these patients and basic science researchers. The knowledge base and experience in addressing MRONJ has expanded, necess...
1,578 CitationsSource
#1Stefano Sivolella (UNIPD: University of Padua)H-Index: 19
#2Franco Lumachi (UNIPD: University of Padua)H-Index: 33
Last. Lorenzo Favero (UNIPD: University of Padua)H-Index: 17
view all 4 authors...
Osteonecrosis of the jaw (ONJ) is a rare but serious lesion of the jaw characterized by exposed necrotic bone and is related to several drugs usually used for treating patients with advanced malignancies. Common therapies inducing ONJ are nitrogen-containing bisphosphonates (BPs), the human monoclonal antibody to the receptor activator of nuclear factor-kappa B ligand denosumab and some anti-angiogenic drugs, alone or in combination with BPs. The real incidence of ONJ is unknown. Several cases o...
80 Citations
PURPOSE: We encountered serious oral mucositis in some patients undergoing colorectal chemotherapy with bevacizumab. We retrospectively investigated the role bevacizumab plays in the occurrence of oral mucositis. SUBJECTS AND METHODS: Between January 2008 and December 2009, we encountered 11 patients for whom chemotherapy with bevacizumab had resulted in oral mucositis. The patients included 5 men and 6 women, with a mean age of 67. 9 years(range, 62-76 years). Among the patients, 5 had grade 1 ...
2 Citations
#1T. Upile (UCL: University College London)H-Index: 7
#2Waseem Jerjes (UCL: University College London)H-Index: 30
Last. Colin Hopper (UCL: University College London)H-Index: 4
view all 9 authors...
Background Saliva is an enriched milieu containing biologically active proteins, including growth factors and cytokines. The endothelial growth factor family of proteins is important for the development of blood and lymphatic vessels in a healthy individual but also can aide tumour growth. The aim of this study is to develop an independent normative database of values of salivary VEGF in a healthy population and to test the hypothesis that values would be raised in the saliva of patients with or...
19 CitationsSource
Cited By0